Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
98,653 results
  • Kappa opioid receptor and oligodendrocyte remyelination. [Journal Article]
    Vitam Horm 2019; 111:281-297Wang F, Mei F
  • Adult oligodendrocyte precursor cells (OPCs) maintain the abilities to differentiate and myelinate denuded axons in demyelinating diseases, such as Multiple Sclerosis (MS), albert often inefficiently. Remyelination therapies seek to enhance endogenous remyelination and represent a promising approach to achieve functional and cellular architectural recovery against neuronal deficits. Recent findin…
  • MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. [Journal Article]
    Brain 2019Morquette B, Juźwik CA, … Fournier AE
  • Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease affecting the brain, spinal cord and optic nerves. Neuronal damage is triggered by various harmful factors that engage diverse signalling cascades in neurons; thus, therapeutic approaches to protect neurons will need to focus on agents that can target multiple biological processes. We have therefore focused…
  • Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. [Journal Article]
    Hum Mol Genet 2019Kagiava A, Richter J, … Kleopa KA
  • X-linked Charcot-Marie-Tooth disease (CMT1X), one of the commonest forms of inherited demyelinating neuropathy, results from GJB1 gene mutations causing loss of function of the gap junction protein connexin32 (Cx32). The aim of this study was to examine whether delayed gene replacement therapy after the onset of peripheral neuropathy can provide a therapeutic benefit in the Gjb1-null/Cx32 knockou…
New Search Next